Michael Friis

Head of Equities

Michael Friis portrait

Latest content

ShowingAll content types

GreenMobility: Launches share buyback programme of up to DKK 6 million

Analyst Comment 01.06.2026 klo 08.30 by Michael Friis
GreenMobility

ExpreS2ion (Investment Case): Q1 2026 - continued progress across pipeline and partner programmes

Research 29.05.2026 klo 09.00 by Michael Friis, Victor Skriver
ExpreS2ion Biotech Holding

ExpreS2ion: Presentation of Q1 2026 report (Recording)

Analyst Comment 28.05.2026 klo 14.02 by Michael Friis
ExpreS2ion Biotech Holding

Join Inderes community

Research, tools and community to support better investment decisions.

FREE account
The market's most popular morning review
Analysts' recommendations and comments
Stock comparison and the investor discussion forum
PREMIUM account
All company reports and analyses
Premium content: model portfolio, insider transactions, Premium articles
Inderes MCP: Inderes data directly into your AI tools
Create account

BioPorto (Investment Case): Q1 2026, advancement on the three pillars central to the long-term potential

Research 22.05.2026 klo 15.30 by Michael Friis, Victor Skriver
BioPorto

SMS (investment case): Second half sets the direction, cost actions and capital reduction in focus

Research 20.05.2026 klo 15.15 by Michael Friis, Victor Skriver
Scandinavian Medical Solutions

ExpreS2ion: Phase I update on ES2B-C001 builds momentum ahead of end-2026 readout

Analyst Comment 19.05.2026 klo 16.25 by Michael Friis
ExpreS2ion Biotech Holding

WindowMaster (Investment case): Macro bites, but structural tailwinds still seem to be there

Research 19.05.2026 klo 16.00 by Michael Friis, Victor Skriver
WindowMaster International

Wirtek (Investment case): Strategy execution shows first proof points

Research 18.05.2026 klo 08.00 by Michael Friis, Victor Skriver
Wirtek

Ascelia Pharma (One pager): On track into the final stretch ahead of July 3 PDUFA

Research 15.05.2026 klo 11.00 by Michael Friis, Victor Skriver
Ascelia Pharma

Ascelia Pharma: Video presentation of the Q1 2026 results

Analyst Comment 14.05.2026 klo 10.21 by Michael Friis
Ascelia Pharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.